198 related articles for article (PubMed ID: 33144420)
21. Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma.
Kawaguchi K; Higuchi T; Li S; Han Q; Tan Y; Igarashi K; Zhao M; Miyake K; Kiyuna T; Miyake M; Ohshiro H; Sugisawa N; Zhang Z; Razmjooei S; Wangsiricharoen S; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Eckardt MA; Singh AS; Singh SR; Eilber FC; Unno M; Hoffman RM
Biochem Biophys Res Commun; 2018 Sep; 503(4):3086-3092. PubMed ID: 30166061
[TBL] [Abstract][Full Text] [Related]
22. Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic.
Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Miyake M; Li S; Han Q; Tan Y; Zhao M; Li Y; Nelson SD; Dry SM; Singh AS; Elliott IA; Russell TA; Eckardt MA; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Eilber FC; Hoffman RM
Cell Cycle; 2018; 17(6):801-809. PubMed ID: 29374999
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of Recombinant Methioninase (rMETase) on Recalcitrant Cancer Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models: A Review.
Kawaguchi K; Han Q; Li S; Tan Y; Igarashi K; Murakami T; Unno M; Hoffman RM
Cells; 2019 May; 8(5):. PubMed ID: 31052611
[TBL] [Abstract][Full Text] [Related]
24. Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer.
Kawaguchi K; Miyake K; Han Q; Li S; Tan Y; Igarashi K; Kiyuna T; Miyake M; Higuchi T; Oshiro H; Zhang Z; Razmjooei S; Wangsiricharoen S; Bouvet M; Singh SR; Unno M; Hoffman RM
Cancer Lett; 2018 Sep; 432():251-259. PubMed ID: 29928962
[TBL] [Abstract][Full Text] [Related]
25. The combination of oral-recombinant methioninase and azacitidine arrests a chemotherapy-resistant osteosarcoma patient-derived orthotopic xenograft mouse model.
Higuchi T; Sugisawa N; Yamamoto J; Oshiro H; Han Q; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Tan Y; Kuchipudi S; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Cancer Chemother Pharmacol; 2020 Feb; 85(2):285-291. PubMed ID: 31705268
[TBL] [Abstract][Full Text] [Related]
26. Combination of oral recombinant methioninase and decitabine arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma patient-derived orthotopic xenograft mouse model.
Higuchi T; Han Q; Miyake K; Oshiro H; Sugisawa N; Tan Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Biochem Biophys Res Commun; 2020 Feb; 523(1):135-139. PubMed ID: 31839218
[TBL] [Abstract][Full Text] [Related]
27. Afterword: Oral Methioninase-Answer to Cancer and Fountain of Youth?
Hoffman RM; Han Q; Kawaguchi K; Li S; Tan Y
Methods Mol Biol; 2019; 1866():311-322. PubMed ID: 30725426
[TBL] [Abstract][Full Text] [Related]
28. Recombinant Methioninase Combined With Tumor-targeting
Igarashi K; Kawaguchi K; Zhao M; Han Q; Tan Y; Kiyuna T; Miyake K; Higuchi T; Nelson SD; Dry SM; Li Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Singh SR; Tsuchiya H; Hoffman RM
Anticancer Res; 2020 May; 40(5):2515-2523. PubMed ID: 32366396
[TBL] [Abstract][Full Text] [Related]
29. Effective Metabolic Targeting of Human Osteosarcoma Cells
Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Murakami T; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Hoffman RM
Anticancer Res; 2017 Sep; 37(9):4807-4812. PubMed ID: 28870899
[TBL] [Abstract][Full Text] [Related]
30. Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models.
Kawaguchi K; Igarashi K; Li S; Han Q; Tan Y; Miyake K; Kiyuna T; Miyake M; Murakami T; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Unno M; Eilber FC; Hoffman RM
Oncotarget; 2018 Jan; 9(1):915-923. PubMed ID: 29416666
[TBL] [Abstract][Full Text] [Related]
31. Triple-Methyl Blockade With Recombinant Methioninase, Cycloleucine, and Azacitidine Arrests a Pancreatic Cancer Patient-Derived Orthotopic Xenograft Model.
Sugisawa N; Yamamoto J; Han Q; Tan Y; Tashiro Y; Nishino H; Inubushi S; Hamada K; Kawaguchi K; Unno M; Bouvet M; Hoffman RM
Pancreas; 2021 Jan; 50(1):93-98. PubMed ID: 33370029
[TBL] [Abstract][Full Text] [Related]
32. Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model.
Kawaguchi K; Igarashi K; Li S; Han Q; Tan Y; Kiyuna T; Miyake K; Murakami T; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Unno M; Eilber FC; Hoffman RM
Oncotarget; 2017 Oct; 8(49):85516-85525. PubMed ID: 29156737
[TBL] [Abstract][Full Text] [Related]
33. Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcoma.
Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Miyaki M; Yamamoto N; Hayashi K; Kimura H; Miwa S; Higuchi T; Singh AS; Chmielowski B; Nelson SD; Russell TA; Eckardt MA; Dry SM; Li Y; Singh SR; Chawla SP; Eilber FC; Tsuchiya H; Hoffman RM
Biochem Biophys Res Commun; 2018 Dec; 506(4):912-917. PubMed ID: 30392912
[TBL] [Abstract][Full Text] [Related]
34. Recombinant-methioninase-producing
Kubota Y; Han Q; Morinaga S; Mizuta K; Bouvet M; Tsunoda T; Hoffman RM
Cancer Diagn Progn; 2023; 3(6):649-654. PubMed ID: 37927811
[TBL] [Abstract][Full Text] [Related]
35. A Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft (PDOX) Mouse Model Is Sensitive to Bevacizumab and Vinorelbine, Regressed by Eribulin and Resistant to Olaparib.
Yamamoto J; Murata T; Tashiro Y; Higuchi T; Sugisawa N; Nishino H; Inubushi S; Sun YU; Lim H; Miyake K; Hongo A; Nomura T; Saitoh W; Moriya T; Tanino H; Hozumi C; Bouvet M; Singh SR; Endo I; Hoffman RM
Anticancer Res; 2020 May; 40(5):2509-2514. PubMed ID: 32366395
[TBL] [Abstract][Full Text] [Related]
36. Recombinant Oral Methioninase (o-rMETase) Combined With Oxaliplatinum Plus 5-Fluorouracil Improves Survival of Mice With Massive Colon-Cancer Peritoneal Carcinomatosis.
Kim MJ; Han Q; Bouvet M; Hoffman RM; Park JH
Anticancer Res; 2023 Jan; 43(1):19-24. PubMed ID: 36585181
[TBL] [Abstract][Full Text] [Related]
37. Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model.
Igarashi K; Kawaguchi K; Li S; Han Q; Tan Y; Gainor E; Kiyuna T; Miyake K; Miyake M; Higuchi T; Oshiro H; Singh AS; Eckardt MA; Nelson SD; Russell TA; Dry SM; Li Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Eilber FC; Hoffman RM
Oncotarget; 2018 Apr; 9(27):19263-19272. PubMed ID: 29721200
[TBL] [Abstract][Full Text] [Related]
38. Oral Recombinant Methioninase Sensitizes a Bladder Cancer Orthotopic Xenograft Mouse Model to Low-dose Cisplatinum and Prevents Metastasis.
Sun YU; Nishino H; Sugisawa N; Yamamoto J; Hamada K; Zhu G; Lim HI; Hoffman RM
Anticancer Res; 2020 Nov; 40(11):6083-6091. PubMed ID: 33109546
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant Oral Recombinant Methioninase Inhibits Lung Metastasis in a Surgical Breast-Cancer Orthotopic Syngeneic Model.
Sugisawa N; Hamada K; Han Q; Yamamoto J; Sun YU; Nishino H; Kawaguchi K; Bouvet M; Unno M; Hoffman RM
Anticancer Res; 2020 Sep; 40(9):4869-4874. PubMed ID: 32878774
[TBL] [Abstract][Full Text] [Related]
40. A Single Low Dose of Eribulin Regressed a Highly Aggressive Triple-negative Breast Cancer in a Patient-derived Orthotopic Xenograft Model.
Lim HI; Yamamoto J; Inubushi S; Nishino H; Tashiro Y; Sugisawa N; Han Q; Sun YU; Choi HJ; Nam SJ; Kim MB; Lee JS; Hozumi C; Bouvet M; Singh SR; Hoffman RM
Anticancer Res; 2020 May; 40(5):2481-2485. PubMed ID: 32366392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
